Randomized, double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty - Kereiakes, DJ; Kleiman, NS; Ambrose, J; Cohen, M; Rodriguez, S; Palabrica, T; Herrman, HC; Sutton, JM; Weaver, D; McKee, DB; Fitzpatrick, V; Sax, FL (J Am Coll Card, 1996)